Latest Insider Transactions at Bio Techne Corp (TECH)
This section provides a real-time view of insider transactions for Bio Techne Corp (TECH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIO-TECHNE Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIO-TECHNE Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 19
2023
|
Roeland Nusse Director |
SELL
Bona fide gift
|
Direct |
377
-1.29%
|
-
|
|
Jan 04
2023
|
Charles R. Kummeth Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
255,837
-18.69%
|
$21,490,308
$84.39 P/Share
|
|
Jan 04
2023
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
407,364
+22.93%
|
$10,591,464
$26.65 P/Share
|
|
Dec 08
2022
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
7,450
-22.21%
|
$610,900
$82.12 P/Share
|
|
Dec 08
2022
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
7,450
+18.17%
|
$230,950
$31.26 P/Share
|
|
Dec 07
2022
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
800
-2.97%
|
$65,600
$82.01 P/Share
|
|
Dec 07
2022
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+2.89%
|
$24,800
$31.26 P/Share
|
|
Oct 27
2022
|
Randolph C Steer Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+5.65%
|
-
|
|
Oct 27
2022
|
Alpna Seth Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+11.23%
|
-
|
|
Oct 27
2022
|
Julie L Bushman Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+25.04%
|
-
|
|
Oct 27
2022
|
Joseph D Keegan Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+11.23%
|
-
|
|
Oct 27
2022
|
Roeland Nusse Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+4.43%
|
-
|
|
Oct 27
2022
|
Rupert Vessey Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+17.76%
|
-
|
|
Oct 27
2022
|
Robert V Baumgartner Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+3.13%
|
-
|
|
Oct 27
2022
|
John L Higgins Director |
BUY
Grant, award, or other acquisition
|
Direct |
338
+5.47%
|
-
|
|
Aug 23
2022
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
663
+14.85%
|
$99,450
$150.78 P/Share
|
|
Aug 11
2022
|
John L Higgins Director |
SELL
Open market or private sale
|
Direct |
512
-4.26%
|
$196,096
$383.09 P/Share
|
|
Aug 10
2022
|
John L Higgins Director |
SELL
Open market or private sale
|
Direct |
1,992
-8.94%
|
$748,992
$376.34 P/Share
|
|
Aug 10
2022
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,400
+29.81%
|
$224,400
$66.9 P/Share
|
|
Aug 08
2022
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
563
+7.95%
|
$99,651
$177.32 P/Share
|
|
Aug 07
2022
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,938
-13.19%
|
$740,316
$382.97 P/Share
|
|
Aug 07
2022
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,938
+21.14%
|
-
|
|
Aug 07
2022
|
Charles R. Kummeth Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,557
-4.59%
|
$4,414,774
$382.97 P/Share
|
|
Aug 07
2022
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,918
+6.29%
|
-
|
|
Aug 07
2022
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
969
-13.98%
|
$370,158
$382.97 P/Share
|
|
Aug 07
2022
|
Brenda S. Furlow SVP - GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
1,969
+22.13%
|
-
|
|
Aug 07
2022
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,214
-27.9%
|
$463,748
$382.97 P/Share
|
|
Aug 07
2022
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,363
+35.19%
|
-
|
|
Jul 28
2022
|
Charles R. Kummeth Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,707
-10.55%
|
$10,528,660
$380.76 P/Share
|
|
Jul 28
2022
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,346
+14.72%
|
$4,897,368
$108.49 P/Share
|
|
Jul 06
2022
|
Charles R. Kummeth Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
30,935
-12.46%
|
$11,198,470
$362.78 P/Share
|
|
Jul 06
2022
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+16.76%
|
$5,400,000
$108.49 P/Share
|
|
Jun 08
2022
|
John L Higgins Director |
SELL
Open market or private sale
|
Direct |
600
-11.53%
|
$219,600
$366.09 P/Share
|
|
Jun 08
2022
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+10.33%
|
$39,600
$66.9 P/Share
|
|
Jun 07
2022
|
Charles R. Kummeth Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,104
-2.51%
|
$1,862,960
$365.0 P/Share
|
|
Jun 07
2022
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,104
+2.45%
|
$551,232
$108.49 P/Share
|
|
Jun 07
2022
|
John L Higgins Director |
SELL
Open market or private sale
|
Direct |
1,000
-17.84%
|
$364,000
$364.31 P/Share
|
|
Jun 07
2022
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+15.14%
|
$66,000
$66.9 P/Share
|
|
May 10
2022
|
Robert V Baumgartner Director |
BUY
Open market or private purchase
|
Direct |
300
+2.88%
|
$105,600
$352.55 P/Share
|
|
Feb 08
2022
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,989
+50.0%
|
$298,350
$150.78 P/Share
|
|
Feb 01
2022
|
William Geist PRESIDENT, PROTEIN SCIENCES |
BUY
Grant, award, or other acquisition
|
Direct |
2,490
+50.0%
|
-
|
|
Jan 28
2022
|
Charles R. Kummeth Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,737
+0.44%
|
$199,755
$115.82 P/Share
|
|
Nov 19
2021
|
Kim Kelderman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
500
-60.0%
|
$252,000
$504.77 P/Share
|
|
Nov 19
2021
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+50.0%
|
$75,000
$150.78 P/Share
|
|
Nov 16
2021
|
Norman David Eansor President-Protein Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
799
+27.4%
|
$99,875
$125.05 P/Share
|
|
Nov 12
2021
|
Norman David Eansor President-Protein Sciences |
SELL
Open market or private sale
|
Direct |
27,159
-21.45%
|
$13,688,136
$504.35 P/Share
|
|
Nov 12
2021
|
Norman David Eansor President-Protein Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
27,159
+48.82%
|
$3,394,875
$125.05 P/Share
|
|
Nov 02
2021
|
James Hippel CFO |
SELL
Open market or private sale
|
Direct |
200
-1.83%
|
$105,000
$525.1 P/Share
|
|
Nov 02
2021
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.79%
|
$25,000
$125.05 P/Share
|
|
Nov 01
2021
|
James Hippel CFO |
SELL
Open market or private sale
|
Direct |
8,822
-13.79%
|
$4,649,194
$527.04 P/Share
|